Alembic Share Price

Pharmaceuticals company Alembic announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue from operations for Q4FY26 was Rs 6,004 lakh, down 19.24% QoQ from Rs 7,434 lakh and down 0.38% YoY from Rs 6,027 lakh. Annual revenue for FY26 increased by 8.16% to Rs 23,999 lakh from Rs 22,189 lakh in FY25. Total Income: Total consolidated income for Q4FY26 stood at Rs 6,218 lakh, a QoQ decrease of 18.88% from Rs 7,665 lakh and a YoY decrease of 1.66% from Rs 6,323 lakh. For the full year FY26, total income was Rs 31,296 lakh. Net Profit After Tax: The consolidated net profit (after tax and share of associate's profit) for Q4FY26 was Rs 6,713 lakh, an increase of 11.64% QoQ from Rs 6,013 lakh and a marginal YoY decrease of 1.93% from Rs 6,845 lakh. For the full year FY26, consolidated net profit grew by 2.16% to Rs 31,738 lakh from Rs 31,068 lakh in FY25. Earnings Per Share (EPS): The basic and diluted EPS for FY26 stood at Rs 12.36 compared to Rs 12.10 in FY25. Standalone Financial Highlights: Revenue from Operations: The company recorded revenue from operations of Rs 5,773 lakh in Q4FY26, representing a QoQ decrease of 20.13% from Rs 7,228 lakh in Q3FY26 and a YoY decrease of 0.84% from Rs 5,822 lakh in Q4FY25. For the full year FY26, revenue stood at Rs 23,193 lakh, up 8.19% from Rs 21,436 lakh in FY25. Total Income: Total income for Q4FY26 was Rs 6,014 lakh, a decrease of 19.14% QoQ from Rs 7,438 lakh and a marginal decrease of 1.41% YoY from Rs 6,100 lakh. Annual total income for FY26 reached Rs 30,470 lakh compared to Rs 28,887 lakh in FY25. Net Profit After Tax: The standalone net profit for Q4FY26 stood at Rs 953 lakh, showing a QoQ decline of 57.19% from Rs 2,226 lakh and a YoY decline of 58.26% from Rs 2,283 lakh. For the full year FY26, net profit was Rs 12,454 lakh, a decrease of 12.26% compared to Rs 14,195 lakh in FY25. Business Highlights: Segment Performance (Consolidated FY26): Active Pharmaceutical Ingredients Business: Revenue increased to Rs 4,659 lakh in FY26 from Rs 3,221 lakh in FY25. The segment profit before tax and interest for the year was Rs 565 lakh. Real Estate Business: Revenue stood at Rs 19,340 lakh in FY26 compared to Rs 18,967 lakh in FY25. The segment profit before tax and interest for the year was Rs 8,117 lakh. Dividend: The Board of Directors has recommended a dividend of Rs 2.40 (120%) per equity share of face value Rs 2/- each for the financial year ended March 31, 2026. Share of Associate Profit: The company's share of profit from its associate (Alembic Pharmaceuticals Limited) was Rs 19,145 lakh for FY26, compared to Rs 16,610 lakh in FY25. Subsidiary Operations: The consolidated results include the performance of Alembic City Limited (Subsidiary), which reported a total revenue of Rs 4,070.97 lakh and a total loss after tax of Rs 214.52 lakh for the year ended March 31, 2026. Labour Code Impact: The company has provisionally estimated the financial implications of new Labour Codes and made an additional provision of Rs 143.72 lakh under 'Employee Benefit Expense' during the quarter ended December 31, 2025. Result PDF

• Trendlyne
• 1 day 19 hours ago

Pharmaceuticals company Alembic announced Q3FY26 results Revenue from operations: Rs 7,434 lakh against Rs 5,792 lakh during Q3FY25, change 28%. PBT: Rs 2,576 lakh against Rs 2,739 lakh during Q3FY25, change -6%. PAT: Rs 2,247 lakh against Rs 2,609 lakh during Q3FY25, change -14%. EPS: Rs 2.34 for Q3FY26. Result PDF

• Trendlyne
• 3 months 1 week ago

The company has received final approval from the US Food & Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, the drug maker said in a statement

• Business Line
• 9 months ago